XENON PHARMACEUTICALS INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
XENON PHARMACEUTICALS INC. (XENE) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $158.63 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2025-02-27
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $158.63M, a 10.99% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $142.93M, a 10.60% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $129.23M, a 7.34% increase from fiscal 2021.
- XENON PHARMACEUTICALS INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2021 was $120.39M, a 9.89% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2024-12-31 | $158.63M 10-K · filed 2025-02-27 |
| 2023-12-31 | $142.93M 10-K · filed 2025-02-27 |
| 2022-12-31 | $129.23M 10-K · filed 2024-02-29 |
| 2021-12-31 | $120.39M 10-K · filed 2023-03-01 |
| 2020-12-31 | $109.56M 10-K · filed 2022-03-01 |
| 2019-12-31 | $101.97M 10-K · filed 2021-03-01 |
| 2018-12-31 | $98.41M 10-K · filed 2020-03-09 |
| 2017-12-31 | $92.80M 10-K · filed 2019-03-06 |
| 2016-12-31 | $87.78M 10-K · filed 2018-03-07 |
| 2015-12-31 | $81.11M 10-K · filed 2017-03-08 |
| 2014-12-31 | $75.57M 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |